GI262570, a peroxisome proliferator-activated receptor γ agonist, changes electrolytes and water reabsorption from the distal nephron in rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 312, Issue 2, 2005, Pages 718-725

  Chen, Lihong ^a,b   Yang, Baichun ^a   McNulty, Judi A ^a   Clifton, Lisa G ^a   Binz, Jane G ^a   Grimes, Angela M ^a   Strum, Jay C ^a   Harrington, W Wallace ^a   Chen, Zibin ^a   Balon, Thomas W ^a   Stimpson, Stephen A ^a   Brown, Kathleen K ^a  

^a GLAXOSMITHKLINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ALDOSTERONE; AMILORIDE; CHLORIDE; ELECTROLYTE; FARGLITAZAR; MESSENGER RNA; MINERALOCORTICOID; POTASSIUM; SODIUM; SODIUM CHANNEL;

ALDOSTERONE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHLORIDE BLOOD LEVEL; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; ELECTROLYTE BLOOD LEVEL; EPITHELIUM CELL; FLUID RETENTION; GENE EXPRESSION; HORMONE RESPONSE; KIDNEY MEDULLA; MALE; NEPHRON; NONHUMAN; PLASMA VOLUME; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RAT; REBOUND; SODIUM ABSORPTION; SODIUM BLOOD LEVEL; SODIUM RETENTION; WATER ABSORPTION;

ACTINS; ALDOSTERONE; AMILORIDE; ANIMALS; BLOOD VOLUME; DIURETICS; ELECTROLYTES; EPITHELIAL CELLS; EPITHELIAL SODIUM CHANNEL; GENE EXPRESSION; KIDNEY MEDULLA; KIDNEY TUBULES, DISTAL; MALE; NEPHRONS; OXAZOLES; PPAR GAMMA; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; SODIUM; SODIUM CHANNELS; TYROSINE; WATER;

EID: 19944434103     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.104.074088     Document Type: Article

References (39)

1. Berger J, Tanen M, Elbrecht A, Hermanowski-Vosatka A, Moller DE, Wright SD, and Thieringer R (2001) Peroxisome proliferator-activated receptor-gamma ligands inhibit adipocyte 11beta-hydroxysteroid dehydrogenase type 1 expression and activity. J Biol Chem 276:12629-12635.
2. Blazer-Yost BL, Esterman MA, and Vlahos CJ (2003) Insulin-stimulated trafficking of ENaC in renal cells requires PI 3-kinase activity. Am J Physiol Cell Physiol 284:C1645-C1653.
3. Brown KK, Faison WL, Hashim M, Harrington WW, Binz JG, and Oliver WR (2000) Antidiabetic efficacy of GI262570 in rodent models of type 2 diabetes. Diabetes 49 (Suppl 1):A278.
4. Callahan MF, Brown KK, Baer PG, and Smith TL (2002) Effects of a PPARgamma agonist, GI262570, on cardiac output (CO), arterial blood pressure (MAP) and systemic vascular resistance (SVR) in conscious rats. Circulation 106 (Suppl II): 111.
5. Chen SY, Bhargava A, Mastroberardino L, Meijer OC, Wang J, Buse P, Firestone GL, Verrey F, and Pearce D (1999) Epithelial sodium channel regulated by aldosterone-induced protein sgk. Proc Natl Acad Sci USA 96:2514-2519.
6. Desvergne B and Wahli W (1999) Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 20:649-688.
7. Eaton DC, Malik B, Saxena NC, Al Khalili OK, and Yue G (2001) Mechanisms of aldosterone's action on epithelial Na+ transport. J Membr Biol 184:313-319.
8. Ecelbarger CA, Kim GH, Wade JB, and Knepper MA (2001) Regulation of the abundance of renal sodium transporters and channels by vasopressin. Exp Neurol 171:227-234.
9. Evans RM (1988) The steroid and thyroid hormone receptor superfamily. Science (Wash DC) 240:889-895.
10. Faletti CJ, Perrotti N, Taylor SI, and Blazer-Yost BL (2002) sgk: an essential convergence point for peptide and steroid hormone regulation of ENaC-mediated Na+ transport. Am J Physiol Cell Physiol 282:C494-C500.
11. Feraille E, Mordasini D, Gonin S, Deschenes G, Vinciguerra M, Doucet A, Vandewalle A, Summa V, Verrey F, and Martin PY (2003) Mechanism of control of Na,K-ATPase in principal cells of the mammalian collecting duct. Ann NY Acad Sci 986:570-578.
12. Fransen R, Boer WH, Boer P, and Koomans HA (1992) Amiloride-sensitive lithium reabsorption in rats: a micropuncture study. J Pharmacol Exp Ther 263:646-650.
13. Ganong WF (2004) The adrenal medulla and adrenal cortex, in Review of Medical Physiology, pp 270-292, Lange Medical Publications, Los Altos, California.
14. Gardiner SM, Nunez DJ, Baer P, Brown K, and Bennett T (2004) Regional hemodynamic effects of the N-(2-benzoylphenyl)-L-tyrosine peroxisome proliferator-activated receptor-gamma ligand, GI 262570 [(S)-2-(2- benzoylphenylamino)-3-[4-[2-(5-methyl-2-phenyl-2-oxazol-4-yl)ethoxy]phenyl] propionic acid], in conscious rats. J Pharmacol Exp Ther 310:1226-1233.
15. Guan Y, Zhang Y, Davis L, and Breyer MD (1997) Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans. Am J Physiol 273:F1013-F1022.
16. Guyton AC and Hall JE (2000) Urine formation by the kidneys: II. Tubular processing of the glomerular filtrate, in Textbook of Medical Physiology (Schmitt W, Gruliow R, Faber P, Norwitz A, and Shaw P eds) pp 295-328, W. B. Saunders Company, Philadelphia, PA.
17. Hollenberg NK (2003) Considerations for management of fluid dynamic issues associated with thiazolidinediones. Am J Med 115 (Suppl 8A):111S-115S.
18. Hong G, Lockhart A, Davis B, Rahmoune H, Baker S, Ye L, Thompson P, Shou Y, O'Shaughnessy K, Ronco P, et al. (2003) PPARgamma activation enhances cell surface ENaCalpha via up-regulation of SGK1 in human collecting duct cells. FASEB J 17:1966-1968.
19. Kermani A and Garg A (2003) Thiazolidinedione-associated congestive heart failure and pulmonary edema. Mayo Clin Proc 78:1088-1091.
20. Loffing J, Summa V, Zecevic M, and Verrey F (2001) Mediators of aldosterone action in the renal tubule. Curr Opin Nephrol Hypertens 10:667-675.
21. McNay JL and Oran E (1970) Possible predisposition of diabetic patients to hyperkalemia following administration of potassium-retaining diuretic, amiloride (MK 870). Metabolism 19:58-70.
22. Mudaliar S, Chang AR, and Henry RR (2003) Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology and clinical implications. Endocr Pract 9:406-416.
23. Naray-Fejes-Toth A, Canessa C, Cleaveland ES, Aldrich G, and Fejes-Toth G (1999) sgk is an aldosterone-induced kinase in the renal collecting duct. Effects on epithelial na+ channels. J Biol Chem 274:16973-16978.
24. Niemeyer NV and Janney LM (2002) Thiazolidinedione-induced edema. Pharmacotherapy 22:924-929.
25. Olefsky JM and Saltiel AR (2000) PPAR gamma and the treatment of insulin resistance. Trends Endocrinol Metab 11:362-368.
26. Palmada M, Embark HM, Yun C, Bohmer C, and Lang F (2003) Molecular requirements for the regulation of the renal outer medullary K(+) channel ROMK1 by the serum- and glucocorticoid-inducible kinase SGK1. Biochem Biophys Res Commun 311:629-634.
27. Ryan MJ, Didion SP, Mathur S, Faraci FM, and Sigmund CD (2004) PPAR(gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice. Hypertension 43:661-666.
28. Schafer JA (2002) Abnormal regulation of ENaC: syndromes of salt retention and salt wasting by the collecting duct. Am J Physiol Renal Physiol 283:F221-F235.
29. Song J, Knepper MA, Hu X, Verbalis JG, and Ecelbarger CA (2004) Rosiglitazone activates renal sodium- and water-reabsorptive pathways and lowers blood pressure in normal rats. J Pharmacol Exp Ther 308:426-433.
30. Tang WH, Francis GS, Hoogwerf BJ, and Young JB (2003) Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure. J Am Coll Cardiol 41:1394-1398.
31. Verrey F (2001) Sodium reabsorption in aldosterone-sensitive distal nephron: news and contributions from genetically engineered animals. Curr Opin Nephrol Hypertens 10:39-47.
32. Verrey F, Loffing J, Zecevic M, Heitzmann D, and Staub O (2003a) SGK1: aldosterone-induced relay of Na+ transport regulation in distal kidney nephron cells. Cell Physiol Biochem 13:21-28.
33. Verrey F, Summa V, Heitzmann D, Mordasini D, Vandewalle A, Feraille E, and Zecevic M (2003b) Short-term aldosterone action on Na,K-ATPase surface expression: role of aldosterone-induced SGK1? Ann NY Acad Sci 986:554-561.
34. Wang F, Aleksunes LM, Reagan LA, and Vergara CM (2002) Management of rosiglitazone-induced edema: two case reports and a review of the literature. Diabetes Technol Ther 4:505-514.
35. Webster MK, Goya L, and Firestone GL (1993) Immediate-early transcriptional regulation and rapid mRNA turnover of a putative serine/threonine protein kinase. J Biol Chem 268:11482-11485.
36. Willson TM, Brown PJ, Sternbach DD, and Henke BR (2000) The PPARs: from orphan receptors to drug discovery. J Med Chem 43:527-550.
37. Yang B, Clifton LG, McNulty JA, Chen L, Brown KK, and Baer PG (2003) Effects of a PPARgamma agonist, GI262570, on renal filtration fraction and nitric oxide level in conscious rats. J Cardiovasc Pharmacol 42:436-441.
38. Yang T, Michele DE, Park J, Smart AM, Lin Z, Brosius FC III, Schnermann JB, and Briggs JP (1999) Expression of peroxisomal proliferator-activated receptors and retinoid X receptors in the kidney. Am J Physiol 277:F966-F973.
39. Zanchi A, Chiolero A, Maillard M, Nussberger J, Brunner HR, and Burnier M (2004) Effects of the peroxisomal proliferator-activated receptor-gamma agonist pioglitazone on renal and hormonal responses to salt in healthy men. J Clin Endocrinol Metab 89:1140-1145.